Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Next Previous
X
Search
Trial Profile

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 063
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 09 Dec 2021 Status changed from active, no longer recruiting to completed.
    • 20 Mar 2020 Results from an analysis predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib using radiomics signatures from 3 trials (CheckMate017, CheckMate063 and NCT00588445) published in the Clinical Cancer Research.
    • 14 Aug 2019 Results evaluating the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival using pooled data from 4 clinical studies (CheckMate 017, 057, 063, and 003) published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top